Trade magazine questioned the effectiveness of Russian vaccine

The lancet note on the Russian vaccine controversy / web

The journalist Nelson Castro, in his program “El Corresponsal”, diffused on the cable TN, presented last night a report on the Russian vaccine.

After making an introduction on the position adopted by the government of Alberto Fernández regarding the acquisition of millions of doses, which would be applied, according to said officials, before the end of the year, he directly attacked the effectiveness of Sputnik V. Al least what has been shown so far.

Nelson Castro assured that the vaccine has not yet completed the phase of studies to validate its immune power and showed an excerpt from the British journal specializing in medical issues, The Lancet, where precisely the great controversy that exists around of Sputnik is discussed in the scientific field, due to the lack of certifications and safety protocols.

“The Russian government has shown horrible manipulation,” said the driver, adding: “The vaccine report is pithy. It contains clear and concrete critiques. Let us remember that The Lancet is like the Bible in terms of Medicine “.

MISCELLANEOUS IN THE FILE

The Argentine government is negotiating with five of the ten producers of coronavirus vaccine candidates who are in phase 3, the final stage of clinical studies, which would allow millions of doses to be obtained from December which can be applied as soon as they are approved. by regulators.

These doses would be in addition to the more than 9 million that will be obtained through Covax (a collective purchasing mechanism promoted by the WHO) which would arrive at the end of February.

These are vaccines from AstraZeneca, Pfizer, Sinopharm, Janssen and the Gamaleya Research Institute (Sputnik V), three of which are conducting clinical studies in the country.

To date, 219 vaccine candidates have been developed worldwide, of which nearly 40 are already tested in humans (clinical phase) and ten are in the final stage of testing, which means that they have passed the previous phases demonstrating acceptable levels of safety (did not cause serious adverse effects) and antibody generation.

In phase 3, the studies envision a larger number of patients and seek to compare the number of people who had COVID-19 between those who received the vaccine and those who received the placebo, in addition to continuing to monitor antibodies and Security.